If you have been reading about peptide analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
==== General paleoanthropology ==== Cerrito, Burkart & van Schaik (2026) review the techniques used to extract information on life history from hominin fossils. Towle (2026) reviews longstanding issues in the systematics of hominins, including non-monophyly of at least the genus Australopithecus and mosaic trait distribution among hominin taxa, and proposes to subsume the genera Paranthropus and Australopithecus within the genus Homo. Begun (2026) reviews the fossil record of African apes and humans, and argues that the lack of hominin fossils from Africa from the interval between 13.5 and 6–7 million years ago might not simply be the result of incompleteness of the fossil record, and is potentially consistent with the origin of hominins in Eurasia and their dispersal into Africa after 7 million years ago. Gardner et al. (2026) study changes of body size throughout the evolutionary history of hominins, and interpret their finding as consistent with marked body mass increase in members of the genus Homo other than Homo habilis and Homo rudolfensis. A study on the morphological diversity of the femur and the humerus in extant hominids is published by Aramendi (2026), who interprets her findings as indicative of variable utility of different long bones for taxonomic indentification of hominin fossils, and as indicating that some of the variability observed in isolated or fragmentary hominin fossils might not be caused by presence of more than one taxon in the studied fossil material.
Petroleum is used to manufacture a wide variety of materials essential for modern life, and it is estimated that the world consumes about 100 million barrels (16 million cubic metres) each day. Petroleum production played a key role in industrialization and economic development, especially after the Second Industrial Revolution. Some petroleum-rich countries, known as petrostates, gained significant economic and international influence during the latter half of the 20th century due to their control of oil production and trade. Petroleum is a non-renewable natural resource, and its exploitation is damaging to the natural environment, climate system and human health. Extraction, refining and burning of petroleum fuels counteract carbon sinks by releasing large quantities of greenhouse gases back into the Earth's atmosphere, making petroleum one of the major contributors to anthropogenic climate change. Other negative environmental effects, at almost all stages of use, include direct release—such as oil spills—and secondary pollution of air and water sources. Proximity to petroleum deposits, and subsequent access to and pricing of oil have historically fueled both domestic and geopolitical conflicts, state-sanctioned oil wars, diplomatic and trade frictions, energy policy disputes and other resource conflicts. While production is estimated to reach peak oil before 2035, global economic focus on climate change mitigation in the transition to renewable energy sources and increased electrification will greatly reduce dependency on petroleum.
=== Synthesis === Dezocine [(−)-13β-amino-5,6,7,8,9,10,11,12-octahydro-5α-methyl-5,11-methanobenzocyclodecen-31-ol, hydrobromide] is a pale white crystal powder. It has no apparent odor. The salt is soluble at 20 mg/ml, and a 2% solution has a pH of 4.6. The synthesis of dezocine begins with the condensation of 1-methyl-7-methoxy-2-tetralone with 1,5-dibromopentane through use of NaH or potassium tert-butoxide. This yields 1-(5-bromopentyl)-1-methyl-7-methoxy-2-tetralone, which is then cyclized with NaH to produce 5-methyl-3-methoxy-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzocyclodecen-13-one. The product is then treated with hydroxylamine hydrochloride, to yield an oxime. A reduction reaction in hydrogen gas produces an isomeric mixture, from which the final product is crystallized and cleaved with HBr.
Emulsifiers Stabilizers Nutritive sweeteners Characterizing flavoring ingredients (with or without coloring) as follows: Fruit and fruit juice (including concentrated fruit and fruit juice). Natural and artificial food flavoring.
Sources: en.wikipedia.org
Psylocke is the alias of two connected characters appearing in American comic books published by Marvel Comics, commonly in association with the X-Men. Both characters are depicted as mutants, a subspecies of humans born with an "X-gene" that grants superhuman abilities. In the primary continuity of the Marvel Universe, the first and best-known incarnation of Psylocke is Betsy Braddock (created by Chris Claremont and Herb Trimpe), a British telepath who was introduced as a supporting character for her twin brother Brian in 1976. Betsy adopts the codename "Psylocke" upon joining the X-Men in 1986, and three years later takes on the appearance of a Japanese woman and the abilities of a ninja in a story written by Claremont and illustrated by Jim Lee. This redesign was retroactively revealed in 1993 as the result of a body swap with the ninja assassin Kwannon (created by Fabian Nicieza and Andy Kubert). Following 29 years of publication history, both women were returned to their respective bodies, and Betsy assumed the mantle of Captain Britain from her brother while Kwannon became the second Psylocke. The Ultimate Universe features two versions of Psylocke: Sai and Kanon Sainouchi (both created by Peach Momoko). In addition to their presence in numerous X-related team titles over the decades, both iterations of Psylocke have been featured in various limited series and one-shots. In 1997, Betsy Braddock, as Psylocke, appeared in the 4-issue team-up series Psylocke and Archangel: Crimson Dawn.
=== Preferred habitat === Bowfin prefer vegetated sloughs, lowland rivers and lakes, swamps, and backwater areas, and are occasionally found in brackish water. They are well camouflaged and difficult to spot in slow water with abundant vegetation. They often seek shelter under roots and submerged logs. Oxygen-poor environments can be tolerated because of their ability to breathe air.
== Structure == The URP gene is located on the 3q28 chromosome of humans. The mature URP peptide is only 8 peptides long making it smaller than UII. URP is also the same across all vertebrates because it has the same cleaving site unlike UII whose cleaving sites vary among species making its sequence different for all species. URP has the same cysteine bridged hexapeptide ring with the sequence CFWKYC as UII. This is known as the core and is the major site of action on the peptide. Destruction of the core leads to immediate loss of biological activity. On the other hand, the amino terminus of URP doesn’t seem to contain any relevant information because it can be modified without any loss in pharmacological activity. Unlike UII, URP doesn’t have an acidic amino acid (either glutamic acid or aspartic acid) preceding its core. It is still a potent agonist for the UII- receptor which suggests that this acidic amino acid is not required for activation of the receptor. The peptide sequence for URP is:
Lymph is circulated in the body via muscle contraction and drains into the lymphatic ducts, which empty into the subclavian veins, returning fluid into blood circulation. A lymph node is an organised collection of lymphoid tissue through which the lymph passes on its way back to the blood. Lymph nodes are particularly numerous in the mediastinum, neck, pelvis, axilla, and inguinal region. Gut-associated lymphoid tissue, including Peyer's patch, plays a major role in the immune system. The spleen produces immune cells to fight antigens in its white pulp, removes particulate matter and aged blood cells, mainly red blood cells in its red pulp, and produces blood cells during fetal life.
=== Polishing === Polishing is used in UPW systems to further reduce the already low-level of contaminants present after primary treatment. UV light is often used at this step to sterilize water. Further deionization is conducted using ion exchange beds or electrodeionization. Both inorganic ions (including silicate) and organic ions are removed through these processes. Ion-exchange beds used in the final polishing steps may be non-regenerable in contrast to those used in earlier steps. Ultrafiltration membranes with pore sizes of 0.45 μm are used to remove small particles including bacteria killed by UV sterilization. In semiconductor applications, additional filters with pore sizes ≤200 nm are typically used just before distribution to further reduce particle contamination. Particles must be filtered down to a "critical particle size" that is one-half of the smallest feature size on a semiconductor chip. For example, chips containing a 40 nm features should have all particles >20 nm (0.02 μm) removed to avoid contamination that prevents computer chips from functioning. After polishing, UPW is typically cycled continuously through the polishing system to prevent stagnation that can lead to bacterial growth.
Sources: en.wikipedia.org
With a $30–45 million production budget, filming began on 12 November 2010 in Cape Town and took approximately 13 weeks, with second unit photography occurring over seven weeks. Filming locations included Johannesburg and Cape Town Film Studios (Dredd was the first project filmed at the studio). The project involved a majority of Cape Town crew members and about 40 imported crew. The producers chose to film in South Africa because of the lowered cost of employing cast and crew compared to locations in Europe and North America, and government incentives that offered to rebate up to 25% of the production costs. The film was shot digitally and primarily in 3D using RED MX, SI2K and Phantom Flex high-speed cameras for the Slo-Mo sequences, producing 4,000 frames per second. Multiple camera rigs were used. Some 2D elements were converted to 3D in post-production. DNA Films' co-founder Andrew Macdonald engaged cinematographer Anthony Dod Mantle to manage the shoot; it was the first time Mantle had worked with 3D. The filmmakers wanted Dredd to have a realistic, visceral look, and drew inspiration from crime and gangster films. For scenes conveying the time and space altering effects of Slo-Mo, Mantle aimed to create images that would be beautiful but disorienting. Mega-City One and its high-rise towers were created in Cape Town Film Studios. Finding a suitable set for the expansive Peach Trees atrium proved difficult, and the producers did not want to build an expensive set.
==== Magnetic particles ==== For magnetic particle separations a droplet of solution containing the analyte of interest is placed on a digital microfluidics electrode array and moved by the changes in the charges of the electrodes. The droplet is moved to an electrode with a magnet on one side of the array with magnetic particles functionalized to bind to the analyte. Then it is moved over the electrode, the magnetic field is removed and the particles are suspended in the droplet. The droplet is swirled on the electrode array to ensure mixing. The magnet is reintroduced and the particles are immobilized and the droplet is moved away. This process is repeated with wash and elution buffers to extract the analyte. Magnetic particles coated with antihuman serum albumin antibodies have been used to isolate human serum albumin, as proof of concept work for immunoprecipitation using digital microfluidics.5 DNA extraction from a whole blood sample has also been performed with digital microfluidics.3 The procedure follows the general methodology as the magnetic particles, but includes pre-treatment on the digital microfluidic platform to lyse the cells prior to DNA extraction.
Based on the existing evidence, the WHO concluded that the origin of the virus was still unknown, and the Chinese government insisted that the market was not the origin. The Chinese government has long insisted that the virus originated outside China, and until June 2021 denied that live animals were traded at the Huanan market. Some Chinese researchers had published a preprint analysis of the Huanan swab samples in February 2022, concluding that the coronavirus in the samples had likely been brought in by humans, not the animals on sale, but omissions in the analysis had raised questions, and the raw sample data had not yet been released. On 4 March 2023, the data from the swab samples of the Huanan live-animal market were released, or possibly leaked; a preliminary analysis of this data was reviewed by the international research community, which said that it made an animal origin much more likely. Although the samples do not definitively prove that the raccoon dog is the "missing" intermediate animal host in the bat-to-human transmission chain, it does show that common raccoon dogs were present in the Huanan market at the time of the initial SARS-CoV-2 outbreak, in areas that were also positive for SARS-CoV-2 RNA, and substantially strengthens this hypothesis as the proximal origin of the pandemic. An attempt by these researchers to collaborate with the Chinese researchers was not answered, but the raw data was removed from the online database.
According to the online portal Box Office Mojo and the review aggregate site Rotten Tomatoes, DiCaprio's most critically and commercially successful films include What's Eating Gilbert Grape (1993), Romeo + Juliet (1996), Titanic (1997), Catch Me If You Can (2002), Gangs of New York (2002), The Aviator (2004), The Departed (2006), Blood Diamond (2006), Revolutionary Road (2008), Shutter Island (2010), Inception (2010), Django Unchained (2012), The Great Gatsby (2013), The Wolf of Wall Street (2013), The Revenant (2015), Once Upon a Time in Hollywood (2019), Don't Look Up (2021), Killers of the Flower Moon (2023), and One Battle After Another (2025). His films have grossed $7.2 billion worldwide. DiCaprio has been recognized with seven nominations, including one win, by the Academy of Motion Picture Arts and Sciences for the following:
Carpal Tunnel Syndrome Fact Sheet (National Institute of Neurological Disorders and Stroke) Archived 2016-03-03 at the Wayback Machine NHS website carpal-tunnel.net provides a free to use, validated, online self diagnosis questionnaire for CTS "Carpal Tunnel Syndrome". MedlinePlus. U.S. National Library of Medicine.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.